On the Record · Kamada
Kamada competitors, on the record
The companies Kamada itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Kamada names
| Company | Named in |
|---|---|
| ADMA Biologics Inc. | 2025 |
| AstraZeneca AB | 2025 |
| Biotest AG | 2025 |
| CSL Behring | 2025 |
| GlaxoSmithKline | 2025 |
| Grifols S.A. | 2025 |
| Kedrion | 2025 |
| Novartis AG | 2025 |
| Octapharma | 2025 |
| Sanofi | 2025 |
| Takeda | 2025 |
| Talecris Biotherapeutics, Inc. | 2025 |
In its own words
ADMA Biologics Inc., Biotest AG, CSL Behring, Grifols S.A., Kedrion, Octapharma, Takeda, Talecris Biotherapeutics, Inc.
Word for word“These large competitors include CSL Behring, Takeda, and Grifols S.A. (“Grifols”), which acquired a previous competitor, Talecris Biotherapeutics, Inc. (“Talecris”) in 2011, Octapharma, Kedrion (other than for KEDRAB), Biotest AG and ADMA Biologics Inc. (“ADMA”).” 20-F for 2025
AstraZeneca AB, GlaxoSmithKline, Novartis AG, Sanofi
Word for word“In other specialties and biosimilar products, we compete with products produced by some of the largest pharmaceutical manufacturers in the world, such as Novartis AG, AstraZeneca AB, Sanofi and GlaxoSmithKline.” 20-F for 2025
Read from Kamada’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-03-11. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.